$VANI News

Last published 3h ago

3h agoVANIVivani Medical, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 8.01 Item 9.01
20h agoVANIVivani Medical Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireTop-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated for announcement later this week
1mo agoVANIVivani Medical Announces Participation in Upcoming Investor ConferencesGlobeNewswireALAMEDA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting
2mo agoVANIVivani Medical Announces Participation in Upcoming Investor ConferencesGlobeNewswireALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
3mo agoVANIVivani Medical Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAll participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in
3mo agoCLRO NTHI IOVA ENSC+1Why Investors Are Watching These Healthcare MoversGlobeNewswireDENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ:CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in
3mo agoVANIVivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight ManagementGlobeNewswireDosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial design to characterize
4mo agoVANIVivani Medical to Present at the Emerging Growth Conference on July 15, 2026GlobeNewswireALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug
4mo agoVANIVivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight ManagementGlobeNewswireALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, ultra long-acting drug
4mo agoCLRO VANIClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani MedicalBusiness WireClearOne, Inc. (NASDAQ:CLRO) ("ClearOne") announced today that it has entered into a definitive agreement and plan of merger (the "Agreement") among its wholly-owned subsidiary ("MergerSub"),
4mo agoVANI CLROVivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.GlobeNewswireVivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (NASDAQ:CLRO), and change the listed company’s name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) and "CRGT"
4mo agoVANI FDMTVivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean BakerGlobeNewswireALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
4mo agoVANIVivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight ManagementGlobeNewswireALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
4mo agoVANIVivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International ConventionGlobeNewswireALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting
5mo agoVANIVivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026GlobeNewswireALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants,
6mo agoVANIVivani Medical Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireInitiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents,
7mo agoVANIVivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireSuccessful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for
9mo agoVANIVivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026GlobeNewswireCortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the
9mo agoVANIVivani Medical, Inc. Announces Closing of Common Stock OfferingGlobeNewswireALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today
9mo agoVANIVivani Medical, Inc. Announces Pricing of Common Stock OfferingGlobeNewswireALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today
9mo agoVANIVivani Subsidiary Cortigent to Present Orion System's Advanced Brain Implant Technology in Poster Session at NANS 2026GlobeNewswireCortigent is a leading developer of brain interface devices based on precision neurostimulation technology The company's new Orion cortical stimulation system for visual perception, designed to treat most common forms
12mo agoVANIVivani Medical Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireCompany plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging
1y agoVANIVivani Medical, Inc. Announces Closing of Common Stock OfferingGlobeNewswireALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today
1y agoVANIVivani Medical, Inc. Announces Pricing of Common Stock OfferingGlobeNewswireALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today
1y agoVANIVivani Medical to Present at the ThinkEquity Conference on October 30, 2025GlobeNewswireALAMEDA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today
1y agoVANIVivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-OffGlobeNewswireALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today
1y agoVANIVivani Medical to Present at the Emerging Growth Conference on September 25, 2025GlobeNewswireALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants,
1y agoVANIVivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to ShareholdersGlobeNewswireCortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly
1y agoVANIVivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight ManagementGlobeNewswireNPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance
1y agoVANIVivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025GlobeNewswireALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants,
1y agoVANIVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsGlobeNewswireCompany plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115
1y agoVANIVivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115GlobeNewswireLIBERATE-1, the first-in-human application of Vivani's NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study's primary
1y agoVANIVivani Medical Appoints Anthony Baldor as Chief Financial OfficerGlobeNewswireALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today
1y agoVANIVivani Medical to Present at the 2025 BIO International ConventionGlobeNewswireALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants,
1y agoVANIVivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani ShareholdersGlobeNewswireTransaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual Cortical
1y agoVANIVivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial ResultsGlobeNewswireAll subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are
1y agoVANIVivani Medical to Present at the American Association of Pharmaceutical Scientists' "Beyond GLP1s: Where the Science will Take Business Next" Virtual WorkshopGlobeNewswireALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants,
1y agoVANIVivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & CompanyGlobeNewswirePortfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to discuss the Company's
1y agoVANIVivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and LongevityGlobeNewswireALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature,
1y agoVANIVivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireSuccessful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139
1y agoVANIVivani Medical Announces $8.25M Private Placement Equity FinancingGlobeNewswireFinancing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development
1y agoVANIVivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly DosingGlobeNewswireNanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20%
1y agoVANIVivani Medical to Present at the Emerging Growth Conference on March 27, 2025Business WireVivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it will present at the Emerging
1y agoVANIVivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight AdultsBusiness WireMiniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management NPM-115 has demonstrated comparable preclinical weight loss to injections of semaglutide, the active ingredient in
1y agoVANIVivani Medical Announces Intent to Spin Off Cortigent Neurostimulation BusinessBusiness WirePlanned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent's Orion® artificial vision system, which is in development to treat blindness, completed an initial 6-year
1y agoVANIVivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in AustraliaBusiness WireNPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration Study represents the first clinical application of
1y agoVANIVivani Medical to Present at the Innovation in Obesity Therapeutics Summit West CoastBusiness WireVivani Medical, Inc.
1y agoVANIVivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial ResultsBusiness WireRegulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese or overweight individuals in Australia Miniature, ultra long-acting GLP-1 implant produced
2y agoVANIVivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024Business WireVivani Medical, Inc. (NASDAQ:VANI) (the "Company" or "Vivani"), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at two upcoming
2y agoVANIVivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in AustraliaBusiness WireNPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, the active ingredient in Ozempic®/Wegovy®, with twice-yearly